JNJ-26483327
As of the edition of 20 October 2026, JNJ-26483327 is a small molecule: went quiet in 2008; acts on ERBB2, ERBB4 and FLT4 and 5 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2008
- Kind
- Small molecule
- Registered trials
- 1, 0 stopped early
- Disease areas
- Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
7 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product7 company-target rows are on route A because of JNJ-26483327.
See the 7 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | P04626 |
| LCK | Tyrosine-protein kinase Lck | P06239 |
| FYN | Tyrosine-protein kinase Fyn | P06241 |
| YES1 | Tyrosine-protein kinase Yes | P07947 |
| LYN | Tyrosine-protein kinase Lyn | P07948 |
| SRC | Proto-oncogene tyrosine-protein kinase Src | P12931 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| ERBB4 | Receptor tyrosine-protein kinase erbB-4 | Q15303 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Lead sponsor of trials | 2006 to now |